202 related articles for article (PubMed ID: 29911543)
1. [The RARE 2017 meeting and the French Foundation of Rare Diseases].
Mandel JL
Med Sci (Paris); 2018 May; 34 Hors série n°1():8. PubMed ID: 29911543
[No Abstract] [Full Text] [Related]
2. Rare diseases band together toward change in research.
Ainsworth C
Nat Med; 2020 Oct; 26(10):1496-1499. PubMed ID: 33029019
[No Abstract] [Full Text] [Related]
3. [A dream becoming reality].
Pouget J
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():7. PubMed ID: 30943152
[No Abstract] [Full Text] [Related]
4. [Place of the expert patient in the R&D process in the field of rare diseases].
Aïach K
Med Sci (Paris); 2018 May; 34 Hors série n°1():28-29. PubMed ID: 29911552
[No Abstract] [Full Text] [Related]
5. [Needs for more R&D in the field of rare diseases].
Tiennot-Herment L
Med Sci (Paris); 2018 May; 34 Hors série n°1():48-49. PubMed ID: 29911563
[No Abstract] [Full Text] [Related]
6. Bone and joint diseases around the world. USA: arthritis foundation research, collaboration, and advocacy.
Riggin DL
J Rheumatol Suppl; 2003 Aug; 67():32. PubMed ID: 12926649
[No Abstract] [Full Text] [Related]
7. [Introduction and welcome message].
Schwebig A; Levy N; Ayme S
Presse Med; 2012 May; 41 Suppl 1():S1-2. PubMed ID: 22483772
[No Abstract] [Full Text] [Related]
8. [The RARE 2017 meeting for companies developing products for rare patients].
Ferry A
Med Sci (Paris); 2018 May; 34 Hors série n°1():7. PubMed ID: 29911542
[No Abstract] [Full Text] [Related]
9. Novartis Foundation to close its doors.
Abbott A
Nature; 2008 Jan; 451(7176):233. PubMed ID: 18202610
[No Abstract] [Full Text] [Related]
10. Symposium zeroes in on new discoveries in breast cancer.
Printz C
Cancer; 2011 Mar; 117(6):1107-8. PubMed ID: 21381004
[No Abstract] [Full Text] [Related]
11. [The RARE 2017 meeting from a patient organisation perspective].
Triclin-Conseil N
Med Sci (Paris); 2018 May; 34 Hors série n°1():4-5. PubMed ID: 29911540
[No Abstract] [Full Text] [Related]
12. [Round table 1. PNMR 2011-2014: point of view of the stakeholders].
Med Sci (Paris); 2014 Apr; 30 Spe(1):8-13. PubMed ID: 24755171
[No Abstract] [Full Text] [Related]
13. [EPI-CLIN 7: a turning point!].
Chêne G; Levêque A
Rev Epidemiol Sante Publique; 2014 Feb; 62 Suppl 2():S35. PubMed ID: 24486202
[No Abstract] [Full Text] [Related]
14. [Biotherapies: a revolution on the move].
Braun S
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():8-12. PubMed ID: 30943153
[No Abstract] [Full Text] [Related]
15. [French Society of Endocrinology's 33th Congress in Bordeaux].
Gourdy P; Young J
Ann Endocrinol (Paris); 2016 Sep; 77(4):235-6. PubMed ID: 27546385
[No Abstract] [Full Text] [Related]
16. [Not Available].
Med Sci (Paris); 2016 Apr; 32 Spec No 1():29-33. PubMed ID: 27137859
[No Abstract] [Full Text] [Related]
17. [The time has come of a therapeutic (re)positioning of the ultra-rare diseases].
Martinat C; Peschanski M
Med Sci (Paris); 2018 Dec; 34(12):1019-1021. PubMed ID: 30623755
[No Abstract] [Full Text] [Related]
18. [Rare diseases: Innovation laboratories for human health].
Braun S
Presse Med; 2012 May; 41 Suppl 1():S48-50. PubMed ID: 22464890
[No Abstract] [Full Text] [Related]
19. [Not Available].
Med Sci (Paris); 2016 Apr; 32 Spec No 1():4. PubMed ID: 27137852
[No Abstract] [Full Text] [Related]
20. From the 2021 ASCO Annual Meeting.
Killock D
Nat Rev Clin Oncol; 2021 Aug; 18(8):469. PubMed ID: 34158668
[No Abstract] [Full Text] [Related]
[Next] [New Search]
